Suchergebnisse - "Molife, L R"

PubPharm (37)

1

Antitumor activity of ipatasertib combined with chemotherapy : results from a phase Ib study in solid tumors

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von Isakoff, S. | Tabernero, J. | Molife, L. | +18

2

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials : the 12-year Royal Marsden experience

enthalten in: Journal of neuro-oncology | 2018

von Coleman, N. | Michalarea, V. | Alken, S. | +10

3

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience

enthalten in: Journal of neuro-oncology | 2018

von Coleman, N. | Michalarea, V. | Alken, S. | +10

4

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience

enthalten in: Journal of neuro-oncology | 2018

von Coleman, N. | Michalarea, V. | Alken, S. | +10

5

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience

enthalten in: Journal of neuro-oncology | 2018

von Coleman, N. | Michalarea, V. | Alken, S. | +10

6

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

enthalten in: Targeted oncology | 2016

von Mateo, J. | Moreno, V. | Gupta, A. | +15

7

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation : a multistudy analysis of response rates and safety

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Matulonis, U. | Penson, R. | Domchek, S. | +10

8

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

enthalten in: Targeted oncology | 2016

von Mateo, J. | Moreno, V. | Gupta, A. | +15

9

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

enthalten in: Targeted oncology | 2016

von Mateo, J. | Moreno, V. | Gupta, A. | +15

10

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

enthalten in: Targeted oncology | 2016

von Mateo, J. | Moreno, V. | Gupta, A. | +15